ArticleVaccines2021
Comparative Evaluation of Lumpy Skin Disease Virus-Based Live Attenuated Vaccines.
Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 76 citations in OpenAlex.
- Immune and biochemical evaluation of a live attenuated lumpy skin disease vaccine in cattle.Open veterinary journal · 2026Article
- Comparison of whole genome sequencing approaches for Capripox viruses.BMC genomics · 2026Article
- Article
- Review
- Comparative performance of bagging and boosting ensemble models for predicting lumpy skin disease with multiclass-imbalanced data.Scientific reports · 2025Article
- Assessment of Biological Properties of Recombinant Lumpy Skin Disease Viruses with Deletions of Immunomodulatory Genes.Viruses · 2025Article
- A goatpox but not sheeppox heterologous live attenuated vaccines provide complete protection against lumpy skin disease in cattle under experimental conditions.Scientific reports · 2025Article
- Host transcriptome profiling for resistance against lumpy skin disease (LSD).BMC research notes · 2025Article
- Clinical and molecular description of natural infections with an Asian strain of lumpy skin disease virus in Bos indicus.Scientific reports · 2025Article
- Evaluation of an interferon-gamma release assay for early detection of lumpy skin disease virus infection and vaccination in cattle.Microbiology spectrum · 2025Article
- Progress in diagnostic methods and vaccines for lumpy skin disease virus: a path towards understanding the disease.Veterinary research communications · 2025Review
- Phylogenetic Analysis, Morphological Characteristics, and Cellular Tropism of Vaccine-Like Recombinant Strains of Lumpy Skin Disease Virus in China.Transboundary and emerging diseases · 2025Article
- Article
- The Safety and Efficacy of New DIVA Inactivated Vaccines Against Lumpy Skin Disease in Calves.Vaccines · 2024Article
- Lumpy Skin Disease: Insights into Molecular Pathogenesis and Control Strategies.Veterinary sciences · 2024Review
- Assessing Post-Vaccination Seroprevalence and Enhancing Strategies for Lumpy Skin Disease Vaccination in Korean Cattle.Animals : an open access journal from MDPI · 2024Article
- Detection and molecular characterization of lumpy skin disease and bovine papular stomatitis viruses in lumpy skin disease-suspected outbreaks in Tanzania.Virology journal · 2024Article
- Article
- Article
- Potential Inhibitors of Lumpy Skin Disease's Viral Protein (DNA Polymerase): A Combination of Bioinformatics Approaches.Animals : an open access journal from MDPI · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 4 countries.
Funding
Abstract
Vaccines form the cornerstone of any control, eradication and preventative strategy and this is no different for lumpy skin disease. However, the usefulness of a vaccine is determined by a multiplicity of factors which include stability, efficiency, safety and ease of use, to name a few. Although the vaccination campaign in the Balkans against lumpy skin disease virus (LSDV) was successful and has been implemented with success in the past in other countries, data of vaccine failure have also been reported. It was therefore the purpose of this study to compare five homologous live attenuated LSDV vaccines (LSDV LAV) in a standardized setting. All five LSDV LAVs studied were able to protect against a challenge with virulent LSDV. Aside from small differences in serological responses, important differences were seen in side effects such as a local reaction and a Neethling response upon vaccination between the analyzed vaccines. These observations can have important implications in the applicability in the field for some of these LSDV LAVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.